Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: Patients with multiple myeloma who undergo autologous stem cell transplantation (ASCT) and exhibit a complete response (CR) have a superior overall survival and time to progression (TTP). High-dose cyclophosphamide is often used before ASCT for mobilization of hematopoietic stem cells. We hypothesized that cyclophosphamide might further improve CR rates in patients undergoing ASCT. We searched the Mayo Clinic myeloma transplantation database for patients who had stem cell mobilization with hematopoietic growth factor alone or cyclophosphamide and growth factor. The impact of cyclophosphamide on CR rates and TTP was evaluated. Patients and methods: A cohort of 201 patients was identified: 127 mobilized with cyclophosphamide and growth factor and 74 with growth factor alone. There were no statistically significant differences between the 2 cohorts in regard to age, sex, β2-microglobulin level, plasma cell labeling index, cytogenetics, conditioning regimen, or disease status at time of transplantation. Results: Complete response rates were 37.4% and 41.3% (P = 0.6115) for patients mobilized with cyclophosphamide combined with growth factor and growth factor alone, respectively, and TTPs were 19.9 months and 20.9 months (P = 0.59). In a multivariate analysis for TTP, cytogenetics and CR rates were the only independent variables (P = 0.0012 and P < 0.0001, respectively). Conclusion: We conclude that high-dose cyclophosphamide does not increase overall CR rates or improve TTP for patients with myeloma undergoing ASCT.

Original languageEnglish (US)
Pages (from-to)384-388
Number of pages5
JournalClinical Lymphoma and Myeloma
Volume6
Issue number5
DOIs
StatePublished - Mar 2006

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Cyclophosphamide
Intercellular Signaling Peptides and Proteins
Hematopoietic Stem Cell Mobilization
Cytogenetics
Transplantation
Hematopoietic Stem Cells
Plasma Cells
Multivariate Analysis
Databases
Survival

Keywords

  • Apheresis
  • Hematopoietic growth factor
  • Response
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

@article{48d8750ff80e4c6fa6b232fc6edda51f,
title = "Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma",
abstract = "Purpose: Patients with multiple myeloma who undergo autologous stem cell transplantation (ASCT) and exhibit a complete response (CR) have a superior overall survival and time to progression (TTP). High-dose cyclophosphamide is often used before ASCT for mobilization of hematopoietic stem cells. We hypothesized that cyclophosphamide might further improve CR rates in patients undergoing ASCT. We searched the Mayo Clinic myeloma transplantation database for patients who had stem cell mobilization with hematopoietic growth factor alone or cyclophosphamide and growth factor. The impact of cyclophosphamide on CR rates and TTP was evaluated. Patients and methods: A cohort of 201 patients was identified: 127 mobilized with cyclophosphamide and growth factor and 74 with growth factor alone. There were no statistically significant differences between the 2 cohorts in regard to age, sex, β2-microglobulin level, plasma cell labeling index, cytogenetics, conditioning regimen, or disease status at time of transplantation. Results: Complete response rates were 37.4{\%} and 41.3{\%} (P = 0.6115) for patients mobilized with cyclophosphamide combined with growth factor and growth factor alone, respectively, and TTPs were 19.9 months and 20.9 months (P = 0.59). In a multivariate analysis for TTP, cytogenetics and CR rates were the only independent variables (P = 0.0012 and P < 0.0001, respectively). Conclusion: We conclude that high-dose cyclophosphamide does not increase overall CR rates or improve TTP for patients with myeloma undergoing ASCT.",
keywords = "Apheresis, Hematopoietic growth factor, Response, Survival",
author = "Dingli, {David M} and Nowakowski, {Grzegorz S} and Angela Dispenzieri and Martha Lacy and Suzanne Hayman and Litzow, {Mark R} and Gastineau, {Dennis A.} and Morie Gertz",
year = "2006",
month = "3",
doi = "10.3816/CLM.2006.n.014",
language = "English (US)",
volume = "6",
pages = "384--388",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma

AU - Dingli, David M

AU - Nowakowski, Grzegorz S

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Hayman, Suzanne

AU - Litzow, Mark R

AU - Gastineau, Dennis A.

AU - Gertz, Morie

PY - 2006/3

Y1 - 2006/3

N2 - Purpose: Patients with multiple myeloma who undergo autologous stem cell transplantation (ASCT) and exhibit a complete response (CR) have a superior overall survival and time to progression (TTP). High-dose cyclophosphamide is often used before ASCT for mobilization of hematopoietic stem cells. We hypothesized that cyclophosphamide might further improve CR rates in patients undergoing ASCT. We searched the Mayo Clinic myeloma transplantation database for patients who had stem cell mobilization with hematopoietic growth factor alone or cyclophosphamide and growth factor. The impact of cyclophosphamide on CR rates and TTP was evaluated. Patients and methods: A cohort of 201 patients was identified: 127 mobilized with cyclophosphamide and growth factor and 74 with growth factor alone. There were no statistically significant differences between the 2 cohorts in regard to age, sex, β2-microglobulin level, plasma cell labeling index, cytogenetics, conditioning regimen, or disease status at time of transplantation. Results: Complete response rates were 37.4% and 41.3% (P = 0.6115) for patients mobilized with cyclophosphamide combined with growth factor and growth factor alone, respectively, and TTPs were 19.9 months and 20.9 months (P = 0.59). In a multivariate analysis for TTP, cytogenetics and CR rates were the only independent variables (P = 0.0012 and P < 0.0001, respectively). Conclusion: We conclude that high-dose cyclophosphamide does not increase overall CR rates or improve TTP for patients with myeloma undergoing ASCT.

AB - Purpose: Patients with multiple myeloma who undergo autologous stem cell transplantation (ASCT) and exhibit a complete response (CR) have a superior overall survival and time to progression (TTP). High-dose cyclophosphamide is often used before ASCT for mobilization of hematopoietic stem cells. We hypothesized that cyclophosphamide might further improve CR rates in patients undergoing ASCT. We searched the Mayo Clinic myeloma transplantation database for patients who had stem cell mobilization with hematopoietic growth factor alone or cyclophosphamide and growth factor. The impact of cyclophosphamide on CR rates and TTP was evaluated. Patients and methods: A cohort of 201 patients was identified: 127 mobilized with cyclophosphamide and growth factor and 74 with growth factor alone. There were no statistically significant differences between the 2 cohorts in regard to age, sex, β2-microglobulin level, plasma cell labeling index, cytogenetics, conditioning regimen, or disease status at time of transplantation. Results: Complete response rates were 37.4% and 41.3% (P = 0.6115) for patients mobilized with cyclophosphamide combined with growth factor and growth factor alone, respectively, and TTPs were 19.9 months and 20.9 months (P = 0.59). In a multivariate analysis for TTP, cytogenetics and CR rates were the only independent variables (P = 0.0012 and P < 0.0001, respectively). Conclusion: We conclude that high-dose cyclophosphamide does not increase overall CR rates or improve TTP for patients with myeloma undergoing ASCT.

KW - Apheresis

KW - Hematopoietic growth factor

KW - Response

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33646594131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646594131&partnerID=8YFLogxK

U2 - 10.3816/CLM.2006.n.014

DO - 10.3816/CLM.2006.n.014

M3 - Article

C2 - 16640814

AN - SCOPUS:33646594131

VL - 6

SP - 384

EP - 388

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 5

ER -